Carbamazepine (All indications)

Study	Exclusion reasons	Rmk	Reference
Christensen (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019		Indications not specified. Overlapping: Christensen 2019 totally included in a larger study published by Dreier 2023 (longer study period and 5 countries) => use of Dreier 2023 data.	Christensen JAMA Netw Open 2019; 2:e186606 10.1001/jamanetworkopen.2018.6606
Christensen (Carbamazepine) (Controls unexposed NOS) (Indications NOS), 2019		Indications not specified. Overlapping: Christensen 2019 totally included in a larger study published by Dreier 2023 (longer study period and 5 countries) => use of Dreier 2023 data.	Christensen JAMA Netw Open 2019; 2:e186606 10.1001/jamanetworkopen.2018.6606
Daugaard (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2020		Indications not specified. Overlapping between Bjork 2022 and Daugaard 2020 for Intellectual disabilities (2 outcomes), with more pregnancies in Bjork 2022 because longer study period and 5 countries => use of Bjork 2022 data.	Daugaard JAMA Netw Open 2020; 3:e2025570 10.1001/jamanetworkopen.2020.25570
Daugaard (Carbamazepine) (Controls unexposed NOS) (Indications NOS), 2020		Indications not specified. Overlapping between Bjork 2022 and Daugaard 2020 for Intellectual disabilities (2 outcomes), with more pregnancies in Bjork 2022 because longer study period and 5 countries => use of Bjork 2022 data.	Daugaard JAMA Netw Open 2020; 3:e2025570 10.1001/jamanetworkopen.2020.25570
Elkjaer (Carbamazepine), 2018		Overlapping: this publication totally included the data of Elkjaer, 2018, for an higher academic grade => use of Ren 2023. There is no information about the exposure indication.	Elkjaer JAMA Neurol 2018; 75:663-671 10.1001/jamaneurol.2017.5035
Coste (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2020		EXCLUDED: this control group doesn't exist in the article (only in the report). Children with a diagnosis of brain malformation (ICD-10 codes Q00 to Q04 and Q05.0 to Q05.4) during their stay in the maternity unit are excluded.	Coste Sci Rep 2020; 10:17362 10.1038/s41598-020-74409-x
He (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
He (Carbamazepine) (Controls unexposed, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
Gopinath (Carbamazepine), 2015	repeat population groups, duplicate reports (most recent study included)	Overlapping: Thomas 2022 included data on language and cognitive delay, also evaluated in Sreedharan et al., 2018; Thomas 2007 and Gopinath 2015, but with more exposed pregnancies, more relevant control group and older children => Use of Thomas 2022.	Gopinath Epilepsy Res 2015; 117:58-62 10.1016/j.eplepsyres.2015.09.003
Thomas (Carbamazepine), 2007	repeat population groups, duplicate reports (most recent study included)	Overlapping: Thomas 2022 included data on language and cognitive delay, also evaluated in Sreedharan et al., 2018; Thomas 2007 and Gopinath 2015, but with more exposed pregnancies, more relevant control group and older children => Use of Thomas 2022.	Thomas Epilepsia 2007; 48:2234-40 10.1111/j.1528-1167.2007.01376.x